CS263952B1 - Remedy with antiviral effect - Google Patents

Remedy with antiviral effect Download PDF

Info

Publication number
CS263952B1
CS263952B1 CS853018A CS301885A CS263952B1 CS 263952 B1 CS263952 B1 CS 263952B1 CS 853018 A CS853018 A CS 853018A CS 301885 A CS301885 A CS 301885A CS 263952 B1 CS263952 B1 CS 263952B1
Authority
CS
Czechoslovakia
Prior art keywords
formula
compounds
virus
cells
effect
Prior art date
Application number
CS853018A
Other languages
Czech (cs)
English (en)
Inventor
Antonin Rndr Drsc Holy
Ivan Ing Rosenberg
Original Assignee
Holy Antonin
Rosenberg Ivan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Holy Antonin, Rosenberg Ivan filed Critical Holy Antonin
Priority to CS853018A priority Critical patent/CS263952B1/cs
Priority to IL78553A priority patent/IL78553A/xx
Priority to US06/854,087 priority patent/US4724233A/en
Priority to AU56468/86A priority patent/AU586860B2/en
Priority to DK184186A priority patent/DK167342B1/da
Priority to GR861089A priority patent/GR861089B/el
Priority to NZ215939A priority patent/NZ215939A/xx
Priority to CA000507510A priority patent/CA1272956A/en
Priority to EG241/86A priority patent/EG18436A/xx
Priority to PT82457A priority patent/PT82457B/pt
Priority to PH33699A priority patent/PH23112A/en
Priority to EP86105776A priority patent/EP0205826B1/en
Priority to DE8686105776T priority patent/DE3684363D1/de
Priority to JP61097811A priority patent/JPH0692307B2/ja
Priority to ZA863133A priority patent/ZA863133B/xx
Priority to AT86105776T priority patent/ATE73663T1/de
Publication of CS263952B1 publication Critical patent/CS263952B1/cs
Priority to HK217296A priority patent/HK217296A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
CS853018A 1985-04-25 1985-04-25 Remedy with antiviral effect CS263952B1 (en)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect
IL78553A IL78553A (en) 1985-04-25 1986-04-21 Therapeutic compositions of phosphonylmethoxyalkyl adenines
US06/854,087 US4724233A (en) 1985-04-25 1986-04-21 Therapeutical application of phosphonylmethoxyalkyl adenines
AU56468/86A AU586860B2 (en) 1985-04-25 1986-04-22 Therapeutical application of phosphonylmethoxyalkyl adenines
DK184186A DK167342B1 (da) 1985-04-25 1986-04-22 Terapeutisk praeparat til behandling af virussygdomme samt anvendelse af et 9-(fosfonylmetoxyalkyl)adeninderivat til fremstilling af praeparatet
CA000507510A CA1272956A (en) 1985-04-25 1986-04-24 Therapeutical application of phosphonylmethoxy-alkyl adenines
NZ215939A NZ215939A (en) 1985-04-25 1986-04-24 Phosphonyl methoxyadenine antiviral compositions
GR861089A GR861089B (en) 1985-04-25 1986-04-24 Therapeutic application of phosponylmethoxy alkyl ademines
EG241/86A EG18436A (en) 1985-04-25 1986-04-24 Therapeutical application of phosponylmethoxy-alkyl adenines
PT82457A PT82457B (pt) 1985-04-25 1986-04-24 Processo de preparacao de uma composicao farmaceutica com base em fosfonil-metoxi-alquil-adeninas com actividade antiviral
PH33699A PH23112A (en) 1985-04-25 1986-04-24 Therapeutical application of phosphonylmethoxyalkyl adenines
EP86105776A EP0205826B1 (en) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl adenines for the treatment of virus diseases
DE8686105776T DE3684363D1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
JP61097811A JPH0692307B2 (ja) 1985-04-25 1986-04-25 アデニン誘導体の治療的適用
ZA863133A ZA863133B (en) 1985-04-25 1986-04-25 Therapeutical application of phosphonylmethoxyalkyl adenines
AT86105776T ATE73663T1 (de) 1985-04-25 1986-04-25 Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
HK217296A HK217296A (en) 1985-04-25 1996-12-19 Phosphonylmethoxy alkyl adenines for the treatment of virus diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect

Publications (1)

Publication Number Publication Date
CS263952B1 true CS263952B1 (en) 1989-05-12

Family

ID=5369042

Family Applications (1)

Application Number Title Priority Date Filing Date
CS853018A CS263952B1 (en) 1985-04-25 1985-04-25 Remedy with antiviral effect

Country Status (17)

Country Link
US (1) US4724233A (pt)
EP (1) EP0205826B1 (pt)
JP (1) JPH0692307B2 (pt)
AT (1) ATE73663T1 (pt)
AU (1) AU586860B2 (pt)
CA (1) CA1272956A (pt)
CS (1) CS263952B1 (pt)
DE (1) DE3684363D1 (pt)
DK (1) DK167342B1 (pt)
EG (1) EG18436A (pt)
GR (1) GR861089B (pt)
HK (1) HK217296A (pt)
IL (1) IL78553A (pt)
NZ (1) NZ215939A (pt)
PH (1) PH23112A (pt)
PT (1) PT82457B (pt)
ZA (1) ZA863133B (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5047533A (en) * 1983-05-24 1991-09-10 Sri International Acyclic purine phosphonate nucleotide analogs
CS264222B1 (en) * 1986-07-18 1989-06-13 Holy Antonin N-phosphonylmethoxyalkylderivatives of bases of pytimidine and purine and method of use them
US5650510A (en) * 1986-11-18 1997-07-22 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiviral phosphonomethoxyalkylene purine and pyrimidine derivatives
NZ222553A (en) * 1986-11-18 1991-07-26 Bristol Myers Co Phosphonomethoxyalkylene purine and pyrimidine derivatives and pharmaceutical compositions
US5284837A (en) * 1988-05-06 1994-02-08 Medivir Ab Derivatives of purine, process for their preparation and a pharmaceutical preparation
EP0353955A3 (en) * 1988-08-02 1991-08-14 Beecham Group Plc Novel compounds
US5688778A (en) * 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
US5302585A (en) * 1990-04-20 1994-04-12 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Use of chiral 2-(phosphonomethoxy)propyl guanines as antiviral agents
DE69129650T2 (de) * 1990-09-14 1999-03-25 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic, Prag/Praha Wirkstoffvorläufer von Phosphonaten
CA2120743C (en) * 1991-10-11 2005-03-08 John C. Martin Antiviral acyclic phosphonomethoxyalkyl substituted, alkenyl and alkynyl purine and pyrimidine derivatives
US6057305A (en) 1992-08-05 2000-05-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Antiretroviral enantiomeric nucleotide analogs
US5514798A (en) * 1993-06-02 1996-05-07 Gilead Sciences, Inc. Method and cyclic carbonates for nucleotide analogues
US5798340A (en) * 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
JPH09506333A (ja) * 1993-09-17 1997-06-24 ギリアード サイエンシーズ，インコーポレイテッド 治療化合物の投薬方法
NZ283658A (en) * 1994-04-04 1999-09-29 William R Freeman Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides)
US5468752A (en) * 1994-04-04 1995-11-21 Freeman; William R. Treatment of conditions of abnormally increased intraocular pressure by administration of HPMPC and related phosphonylmethoxyalkylcytosines
US5977061A (en) * 1995-04-21 1999-11-02 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic N6 - substituted nucleotide analagues and their use
US6093816A (en) 1996-06-27 2000-07-25 Isis Pharmaceuticals, Inc. Cationic lipids
TWI230618B (en) * 1998-12-15 2005-04-11 Gilead Sciences Inc Pharmaceutical compositions of 9-[2-[[bis[(pivaloyloxy)methyl]phosphono]methoxy]ethyl]adenine and tablets or capsules containing the same
US6635278B1 (en) 1998-12-15 2003-10-21 Gilead Sciences, Inc. Pharmaceutical formulations
US7205404B1 (en) * 1999-03-05 2007-04-17 Metabasis Therapeutics, Inc. Phosphorus-containing prodrugs
ATE322494T1 (de) * 2000-01-07 2006-04-15 Universitaire Instelling Antwe Purin derivate, ihre herstellung und verwendung
KR100749160B1 (ko) 2000-07-21 2007-08-14 길리애드 사이언시즈, 인코포레이티드 포스포네이트 뉴클레오티드 유사체의 전구 약물의 제조방법
CZ297267B6 (cs) 2001-06-29 2006-10-11 Ústav organické chemie a biochemie AV CR Deriváty pyrimidinu nesoucí fosfonátovou skupinu,zpusob jejich prípravy, jejich pouzití pro lécbu a farmaceutické prípravky tyto látky obsahující
WO2004037161A2 (en) * 2002-05-13 2004-05-06 Metabasis Therapeutics, Inc. Cyclic prodrugs of pmea one of its analogues
NZ536327A (en) * 2002-05-13 2007-08-31 Metabasis Therapeutics Inc PMEA and PMPA cyclic producing synthesis
AU2003284800A1 (en) * 2002-11-12 2004-06-03 Tianjin Kinsly Pharmaceutical Co., Ltd. A new crystal form of adefovir dipivoxil and its composition
SI1583542T1 (sl) 2003-01-14 2008-12-31 Gilead Sciences Inc Sestavki in postopki za kombinacijsko antivirusnoterapijo
SI1644389T1 (sl) 2003-06-16 2011-06-30 Acad Of Science Czech Republic Pirimidinske spojine s fosfonatnimi skupinami kot antivirusni nukleotidni analogi
RU2006138907A (ru) * 2004-06-08 2008-07-20 Метабазис Терапеутикс Синтез сложных циклических эфиров с применением кислоты льюиса
CN100338080C (zh) * 2004-06-16 2007-09-19 山东中科泰斗化学有限公司 9－[2－(膦羧基甲氧基)乙基]腺嘌呤双环醇酯及其制备方法
WO2006110157A2 (en) 2004-07-27 2006-10-19 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti hiv agents
ES2401285T3 (es) * 2004-12-16 2013-04-18 The Regents Of The University Of California Fármacos con el pulmón como diana
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
FR2908133B1 (fr) * 2006-11-08 2012-12-14 Centre Nat Rech Scient Nouveaux analogues de nucleotides comme molecules precurseurs d'antiviraux
KR101173892B1 (ko) 2007-06-18 2012-08-16 선샤인 레이크 파르마 컴퍼니 리미티드 브로모-페닐 치환된 티아졸릴 디하이드로피리미딘
TWI444384B (zh) 2008-02-20 2014-07-11 Gilead Sciences Inc 核苷酸類似物及其在治療惡性腫瘤上的用途
US7935817B2 (en) * 2008-03-31 2011-05-03 Apotex Pharmachem Inc. Salt form and cocrystals of adefovir dipivoxil and processes for preparation thereof
NZ612380A (en) 2008-12-09 2015-01-30 Gilead Sciences Inc Modulators of toll-like receptors
JP5642766B2 (ja) 2009-03-26 2014-12-17 ダエウン ファーマシューティカル カンパニー リミテッド アデフォビルジピボキシルの新規結晶形及びその製造方法
US20110223131A1 (en) 2010-02-24 2011-09-15 Gilead Sciences, Inc. Antiviral compounds
CA2819548C (en) 2010-12-10 2019-04-09 Sigmapharm Laboratories, Llc Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs
ES2687958T3 (es) 2013-03-15 2018-10-30 The Regents Of The University Of California Fosfonato diésteres de nucleósido acíclico
WO2015038421A1 (en) 2013-09-10 2015-03-19 Dow Corning Corporation Wear-resistant silicon eutectic alloy components and methods of making the same
EP3105238A4 (en) 2014-02-13 2017-11-08 Ligand Pharmaceuticals, Inc. Prodrug compounds and their uses
WO2015195538A1 (en) 2014-06-17 2015-12-23 Dow Corning Corporation Decorative shape-cast articles made from silicon eutectic alloys, and methods for producing the same
EP3164136A4 (en) 2014-07-02 2018-04-04 Ligand Pharmaceuticals, Inc. Prodrug compounds and uses therof
WO2016001907A1 (en) 2014-07-02 2016-01-07 Prendergast Patrick T Mogroside iv and mogroside v as agonist/stimulator/un-blocking agent for toll-like receptor 4 and adjuvant for use in human/animal vaccine and to stimulate immunity against disease agents.
CN113577081A (zh) 2014-07-11 2021-11-02 吉利德科学公司 用于治疗hiv的toll样受体调节剂
JP6708329B2 (ja) 2014-09-15 2020-06-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ヌクレオチド類似体
AU2016322763A1 (en) 2015-09-15 2018-04-19 Gilead Sciences, Inc. Modulators of toll-like recptors for the treatment of HIV
EP3350191B9 (en) 2015-09-15 2021-12-22 The Regents of the University of California Nucleotide analogs
EP3372227A1 (en) 2017-03-06 2018-09-12 MH10 Spolka z ograniczona odpowiedzialnoscia Tablet formulation of adefovir dipivoxil
US11970482B2 (en) 2018-01-09 2024-04-30 Ligand Pharmaceuticals Inc. Acetal compounds and therapeutic uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1523865A (en) * 1974-09-02 1978-09-06 Wellcome Found Purine compunds and salts thereof
JPS52105195A (en) * 1976-03-01 1977-09-03 Wellcome Found Substituted purine
US4230708A (en) * 1977-10-20 1980-10-28 Stichting Rega V.Z.W. Therapeutic application of (S) -or (RS)-9-(2, 3-dihydroxypropyl) adenine for use as antiviral agents
CS233665B1 (en) * 1983-01-06 1985-03-14 Antonin Holy Processing of isomere o-phosphonylmethylderivative of anantiomere racemic vicinal diene
CS238038B1 (en) * 1983-10-07 1985-11-13 Antonin Holy Medical drug with antivirus effect

Also Published As

Publication number Publication date
NZ215939A (en) 1988-09-29
IL78553A (en) 1989-09-28
PH23112A (en) 1989-04-19
PT82457B (pt) 1988-03-03
EP0205826A2 (en) 1986-12-30
ZA863133B (en) 1987-02-25
AU5646886A (en) 1986-10-30
US4724233A (en) 1988-02-09
EP0205826A3 (en) 1989-05-10
HK217296A (en) 1996-12-27
PT82457A (en) 1986-05-01
DK167342B1 (da) 1993-10-18
ATE73663T1 (de) 1992-04-15
EP0205826B1 (en) 1992-03-18
DK184186A (da) 1986-10-26
EG18436A (en) 1993-02-28
JPS61275218A (ja) 1986-12-05
IL78553A0 (en) 1986-08-31
AU586860B2 (en) 1989-07-27
JPH0692307B2 (ja) 1994-11-16
CA1272956A (en) 1990-08-21
GR861089B (en) 1986-08-26
DK184186D0 (da) 1986-04-22
DE3684363D1 (de) 1992-04-23

Similar Documents

Publication Publication Date Title
CS263952B1 (en) Remedy with antiviral effect
De Clercq Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
De Clercq S-Adenosylhomocysteine hydrolase inhibitors as broad-spectrum antiviral agents
Clercq et al. A novel selective broad-spectrum anti-DNA virus agent
US5321030A (en) Creatine analogs having antiviral activity
De Clercq et al. In vitro susceptibility of varicella-zoster virus to E-5-(2-bromovinyl)-2'-deoxyuridine and related compounds
Park et al. Acyclovir in oral and ganglionic herpes simplex virus infections
Zakirova et al. Phosphoramidate derivatives of acyclovir: Synthesis and antiviral activity in HIV-1 and HSV-1 models in vitro
De Clercq et al. Selective in vitro and in vivo activities of 5-(2-haloalkyl) pyrimidine nucleoside analogs, particularly 5-(2-chloroethyl)-2'-deoxyuridine, against herpes simplex virus
CA2222154A1 (en) Acyclovir derivatives for topical use
KEATING Antiviral agents
De Clercq The antiviral spectrum of (E)-5-(2-bromovinyl)-2′-deoxyuridine
AU623341B2 (en) Antiviral therapy for hepatitis b
JP4545434B2 (ja) 抗ウイルス活性を有する６−‘２−（ホスホノメトキシ）アルコキシピリミジン誘導体
EP0294443B1 (en) Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus
Machida et al. In vitro antiherpesviral activity of 5-alkyl derivatives of 1-β-d-arabinofuranosyluracil
Wingard et al. Activity of trifluorothymidine against cytomegalovirus
JPS59186985A (ja) ジメチルアミノメチレン化された抗ヘルペス化合物
CS238038B1 (en) Medical drug with antivirus effect
CA1328865C (en) Composition and method for treating hepatitis virus infections using 1-(2'-deoxy-2'-fluoro-beta-d-arabino- furanosyl)-5-ethyluracil
Ayisi et al. Combination chemotherapy: interaction of 5-methoxymethyldeoxyuridine with trifluorothymidine, phosphonoformate and acycloguanosine against herpes simplex viruses
Barnard et al. Acyclic phosphonomethylether nucleoside inhibitors of respiratory viruses
Park et al. Efficacy of (E)-5-(2-bromovinyl)-2′-deoxyuridine in the treatment of experimental herpes simplex virus encephalitis in mice
Holliday et al. Inhibition of herpes simplex virus types 1 and 2 replication in vitro by mercurithio analogs of deoxyuridine
Brandi et al. A new homodimer of aciclovir as a prodrug with increased solubility and antiviral activity

Legal Events

Date Code Title Description
MK4A Patent expired

Effective date: 20000425